Mycenax Biotech Inc.
4726
Rank in Stocks
#18079
Mycenax Biotech Inc. specializes in the research, development, and... Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
Share Price
$0.70114255
Last synced: 2026-11-10
Market Cap
$145.17M
Change (1 day)
9.79%
Change (1 year)
-34.64%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Mycenax Biotech Inc. (4726)
Category
Healthcare
Operating Margin for Mycenax Biotech Inc. (4726)
Operating Margin as of November 2026 TTM: -43.43%
According to Mycenax Biotech Inc.'s latest financial reports, its current operating margin (TTM) is -43.43%. At the end of 2025 the company had an operating margin of -54.56%.
Operating Margin history for Mycenax Biotech Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -43.43% | -20.40% |
| 2025 | -54.56% | -19.15% |
| 2024 | -67.48% | -26.86% |
| 2023 | -92.26% | 63.78% |
| 2022 | -56.33% | 373.36% |
| 2021 | -11.90% | -299.33% |
| 2020 | 5.97% | -110.13% |
| 2019 | -58.91% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.89% |
US
|
|
| -149.01% | -96.57% |
US
|
|
| 25.57% | -100.59% |
AU
|
|
| 31.23% | -100.72% |
BE
|
|
| 29.35% | -100.68% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Mycenax Biotech Inc.'s operating margin
What is Mycenax Biotech Inc.'s operating margin?
Mycenax Biotech Inc.'s operating margin is -43.43%, as of Nov 2026.
What was Mycenax Biotech Inc.'s operating margin in 2025?
In 2025, Mycenax Biotech Inc.'s operating margin was -54.56%, compared with -67.48% in 2024.
How has Mycenax Biotech Inc.'s operating margin changed since 2020?
From 2020 to 2025, Mycenax Biotech Inc.'s operating margin was highest in 2020 (5.97%) and lowest in 2023 (-92.26%).
How does Mycenax Biotech Inc.'s operating margin compare with similar companies?
Mycenax Biotech Inc.'s operating margin (-43.43%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.